Founded in 2013, EirGenix is a Biologics Drug Development and Contracts Development and Manufacturing Organization. EirGenix provides high quality and cost-effectiveness service and obtains the cGMP facilities—one for mammalian cells and one for microbial— that are certified by the US FDA, Taiwan FDA and Japan PMDA. All R&D technologies EirGenix provides include cell line establishment, large-scale production process development, analytical method development, GMP quality system operations, and leading EirGenix a world-class biologics drug provider. EirGenix currently has seven products undergoing development. Four antibody products are for treating HER2 gene variance; one antibody biosimilar is for inhibiting angiogenesis, and one carrier protein is for vaccination use.